Home Nucleus Pharmaceuticals U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032

Overview

The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach a 73.12 USD Million by 2032 and is projected to grow at a CAGR of 11.42% from 2025 to 2032.

Revenue, 2024 (USD Million)
30.89
Forecast, 2032 (USD Million)
73.12
CAGR, 2024 - 2032
11.42%
Report Coverage
U.K.

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market 2018-2032 USD Million

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 30.89 USD Million
  • Projected Market Size (2032): 73.12 USD Million
  • CAGR (2025-2032): 11.42%

Key Findings of U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market

  • The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at 30.89 USD Million in 2024.
  • The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is likely to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Beta Emitters in Isotope Segment accounted for the largest share of the market with a revenue of 25.97 USD Million
  • The fastest growing segment Small Molecule Ligands in Vector Type Segment grew Fastest with a CAGR of 13.16% during the forecast period from 2024 to 2032.

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Vector Type
  • Others
  • Monoclonal Antibodies
  • Peptides
  • Small Molecule Ligands
End User
  • Research Institutes
  • Radiopharmacies
  • Hospitals
Therapeutic Application
  • Others
  • Oncology
Isotope
  • Alpha Emitters
  • Beta Emitters
Sources
  • Others
  • Generator-Produced Isotopes
  • Reactor-Produced Isotopes

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Data Coverage Insights

Study Period 2024-2032
Base Year 2024
Unit Revenue in USD Million
Market Value in 2024 30.89 USD Million
Market Value in 2032 73.12 USD Million
CAGR (2025-2032) 11.42%
Historic Data 2016-2023
Market Segments Covered Vector Type,End User,Therapeutic Application,Isotope,Sources

Regional Insights:

  • Leading Market (2024-2032): U.K., leading in terms of revenue 30.89 USD Million in 2024
    • Key Country: U.K., leading in terms of revenue with value of 30.89 USD Million in 2024.

Segments and Scope

  • U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Vector Type
    • Small Molecule Ligands is the largest segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 15.62 USD Million in the year 2024.
    • Small Molecule Ligands is the Fastest growing segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 13.16 % in forecast period 2025-2032.
  • U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By End User
    • Hospitals is the largest segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 17.26 USD Million in the year 2024.
    • Hospitals is the Fastest growing segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 12.40 % in forecast period 2025-2032.
  • U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Therapeutic Application
    • Oncology is the largest segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 23.60 USD Million in the year 2024.
    • Oncology is the Fastest growing segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 11.78 % in forecast period 2025-2032.
  • U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Isotope
    • Beta Emitters is the largest segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 25.97 USD Million in the year 2024.
    • Beta Emitters is the Fastest growing segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 11.46 % in forecast period 2025-2032.
  • U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Sources
    • Reactor-Produced Isotopes is the largest segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 18.86 USD Million in the year 2024.
    • Reactor-Produced Isotopes is the Fastest growing segment in U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 11.56 % in forecast period 2025-2032.

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis

 
Company Name Company Share Analysis
Novartis AG
Eckert & Ziegler
ITM Isotope Technologies Munich SE
SHINE Technologies, LLC
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling

Industry Related Reports

South America Cold Sore Treatment Market
Middle East & Africa Cold Sore Treatment Market
North America Cold Sore Treatment Market
Europe Cold Sore Treatment Market
Asia-Pacific Cold Sore Treatment Market
Argentina Cold Sore Treatment Market
Australia Cold Sore Treatment Market
Austria Cold Sore Treatment Market
Belgium Cold Sore Treatment Market
Brazil Cold Sore Treatment Market
Frequently Asked Questions
The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Vector Type,End User,Therapeutic Application,Isotope,Sources.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 30.89(Revenue in USD Million) in 2024.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The Beta Emitters segment is expected to dominate the U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market, holding a largest market share of 25.97 USD Million in 2024

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Vector Type
  • Others
  • Monoclonal Antibodies
  • Peptides
  • Small Molecule Ligands
End User
  • Research Institutes
  • Radiopharmacies
  • Hospitals
Therapeutic Application
  • Others
  • Oncology
Isotope
  • Alpha Emitters
  • Beta Emitters
Sources
  • Others
  • Generator-Produced Isotopes
  • Reactor-Produced Isotopes
Frequently Asked Questions
The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Vector Type,End User,Therapeutic Application,Isotope,Sources.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 30.89(Revenue in USD Million) in 2024.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The estimated market value of the U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 73.12 (USD Million).

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling

U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Vector Type,End User,Therapeutic Application,Isotope,Sources.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 30.89(Revenue in USD Million) in 2024.
U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The estimated market value of the U.K. Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 73.12 (USD Million).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES